CD274 and non-small cell lung carcinoma: analyzed the extent of PD-1 expression in 128 patients with advanced NSCLC (all histological subgroups, predominantly LUAD) treated with ICIs (anti-programmed death 1, anti-PD-L1, or anti-cytotoxic T-lymphocyte-associated protein 4 antibodies).